101066-57-3

Basic information

• Product Name: 4-Nitro-3-(trifluoromethyl)benzaldehyde
• Synonyms: 4-Nitro-3-(trifluoromethyl)benzaldehyde
• CAS NO: 101066-57-3
• Molecular Formula: C₈H₄F₃NO₃
• Molecular Weight: 219.1174696
• Mol File: 101066-57-3.mol

Chemical Properties

• Boiling Point: 291.9±40.0 °C(Predicted)
• Appearance: /
• Density: 1.496±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 4-Nitro-3-(trifluoromethyl)benzaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Nitro-3-(trifluoromethyl)benzaldehyde(101066-57-3)
• EPA Substance Registry System: 4-Nitro-3-(trifluoromethyl)benzaldehyde(101066-57-3)

Safety Data

• Hazardous Substances Data: 101066-57-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-Nitro-3-(trifluoromethyl)benzaldehyde is used as a key intermediate in the synthesis of pharmaceuticals for its ability to contribute to the development of new drugs with enhanced properties. Its unique structure allows for the creation of compounds with specific therapeutic effects.
Used in Dye Industry:
In the dye industry, 4-Nitro-3-(trifluoromethyl)benzaldehyde is utilized as a precursor in the production of dyes, where its chemical properties contribute to the color and stability of the final products.
Used in Organic Chemistry Research:
4-Nitro-3-(trifluoromethyl)benzaldehyde is employed as a building block in organic chemistry for the synthesis of various bioactive compounds. Its reactivity and structural features make it suitable for exploring new chemical reactions and the development of novel organic molecules.
Used in Material Science:
In the field of material science, 4-Nitro-3-(trifluoromethyl)benzaldehyde is used for its potential applications in creating new materials with specific properties. Its unique chemical structure allows for the engineering of materials with tailored characteristics for various applications.

Upstream product

• 936234-83-2 (4-nitro-3-(trifluoromethyl)phenyl)methanol 
• 320-38-7 4-nitro-3-(trifluoromethyl)benzoic acid 
• 75-09-2 dichloromethane 
• 384-22-5 2-nitrobenzotrifluoride 

Downstream Products

• 936234-84-3 [(3S)-3-(N-benzyloxycarbonyl)amino-3-methoxycarbonylpropyl][(4-nitro-3-trifluoromethylphenyl)hydroxymethyl]phosphinic acid 
• 936234-85-4 [(3S)-3-amino-3-carboxypropyl][(4-nitro-3-trifluoromethylphenyl)hydroxymethyl]phosphinic acid 

Relevant articles and documents

Vicarious Nucleophilic Chloromethylation of Nitroaromatics

Nitroaromatics substituted with electron-acceptor or electron-donor groups undergo vicarious nucleophilic substitution with the lithium salt of dichloromethane to provide chloromethyl-substituted nitroaromatics in good to high yields. The methodology represents a new strategy for the synthesis of benzyl chlorides.

Increased Potency and Selectivity for Group III Metabotropic Glutamate Receptor Agonists Binding at Dual sites

A group III metabotropic glutamate (mGlu) receptor agonist (PCEP) was identified by virtual HTS. This orthosteric ligand is composed by an l-AP4-derived fragment that mimics glutamate and a chain that binds into a neighboring pocket, offering possibilities to improve affinity and selectivity. Herein we describe a series of derivatives where the distal chain is replaced by an aromatic or heteroaromatic group. Potent agonists were identified, including some with a mGlu4 subtype preference, e.g., 17m (LSP1-2111) and 16g (LSP4-2022). Molecular modeling suggests that aromatic functional groups may bind at either one of the two chloride regulatory sites. These agonists may thus be considered as particular bitopic/dualsteric ligands. 17m was shown to reduce GABAergic synaptic transmission at striatopallidal synapses. We now demonstrate its inhibitory effect at glutamatergic parallel fiber-Purkinje cell synapses in the cerebellar cortex. Although these ligands have physicochemical properties that are markedly different from typical CNS drugs, they hold significant therapeutic potential.

Hypophosphorous Acid Derivatives and their Therapeutical Applications

Hypophosphorous acid derivatives having Formula (I) wherein .M is a [C(R3,R4)]n1-C(E,COOR1,N(H,Z)) group, or an optionally substituted Ar—CH(COOR1,N(H,Z)) group, or an a, β, or a β, g-cyclic amino acid; .R1 is H or R, R being an hydroxy or a ca